Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants
d m. n. A. D., Beyer-Westendorf J., Pabinger I.
Annals of Oncology
Vol.30, Issue6, Num.mdz111
Опубликовано: 2019
Тип ресурса: Обзор
DOI:10.1093/annonc/mdz111
Аннотация:
Anticoagulation for cancer-associated venous thromboembolism (VTE) can be challenging due to complications-including bleeding and potential drug-drug interactions with chemotherapy- A ssociated with vitamin K antagonists and inconvenience of low-molecular-weight heparin (LMWH). Direct oral anticoagulants (DOACs) could partially overcome these issues, but until recently there were no large clinical trials assessing their efficacy and safety in cancer patients. This review summarizes clinical treatment guidelines, prior clinical and real-world evidence for anticoagulant choice, recent clinical trials assessing DOACs for cancer-associated VTE (i.e. Hokusai-VTE Cancer, SELECT-D, CARAVAGGIO, and ADAM VTE), and special considerations for DOAC use. Based on established data, clinical guidelines recommend patients with cancer-associated VTE receive LMWH treatment of at least 3-6 months. Nevertheless, LMWH is underused and associated with poor compliance and persistence in these patients relati
Ключевые слова:
cancer; direct oral anticoagulants; treatment; venous thromboembolism
alkylating agent; anthracycline; anticoagulant agent; antimitotic agent; antineoplastic antimetabolite; antineoplastic monoclonal antibody; antivitamin K; apixaban; cyclosporine; dabigatran; dalteparin; DNA topoisomerase inhibitor; edoxaban; glucocorticoid; immunomodulating agent; intercalating agent; low molecular weight heparin; platinum complex; protein tyrosine kinase inhibitor; rivaroxaban; tinzaparin; warfarin; anticoagulant agent; anticoagulant agent; apixaban; dalteparin; edoxaban; low molecular weight heparin; rivaroxaban; anticoagulant agent; apixaban; dalteparin; edoxaban; rivaroxaban; anticoagulant therapy; bleeding; brain hemorrhage; deep vein thrombosis; digestive system cancer; drug antagonism; drug blood level; drug efficacy; drug safety; drug substitution; drug withdrawal; esophagus cancer; gastrointestinal hemorrhage; human; lung embolism; malignant neoplasm; patient compliance; platelet count; priority journal; recurrence risk; Review; subdural hematoma; thrombocytop
Язык текста: Английский
ISSN: 1569-8041
m. n. A. D. m n Ay Dzhikhan 1980-
Beyer-Westendorf J.
Pabinger I.
м. н. А. Д. м н Ай Джихан 1980-
Беьер-Wестендорф Й.
Пабингер И.
Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants
Текст визуальный непосредственный
Annals of Oncology
Oxford University Press
Vol.30, Issue6 Num.mdz111
2019
Обзор
cancer direct oral anticoagulants treatment venous thromboembolism
alkylating agent anthracycline anticoagulant agent antimitotic agent antineoplastic antimetabolite antineoplastic monoclonal antibody antivitamin K apixaban cyclosporine dabigatran dalteparin DNA topoisomerase inhibitor edoxaban glucocorticoid immunomodulating agent intercalating agent low molecular weight heparin platinum complex protein tyrosine kinase inhibitor rivaroxaban tinzaparin warfarin anticoagulant agent anticoagulant agent apixaban dalteparin edoxaban low molecular weight heparin rivaroxaban anticoagulant agent apixaban dalteparin edoxaban rivaroxaban anticoagulant therapy bleeding brain hemorrhage deep vein thrombosis digestive system cancer drug antagonism drug blood level drug efficacy drug safety drug substitution drug withdrawal esophagus cancer gastrointestinal hemorrhage human lung embolism malignant neoplasm patient compliance platelet count priority journal recurrence risk Review subdural hematoma thrombocytop
Anticoagulation for cancer-associated venous thromboembolism (VTE) can be challenging due to complications-including bleeding and potential drug-drug interactions with chemotherapy- A ssociated with vitamin K antagonists and inconvenience of low-molecular-weight heparin (LMWH). Direct oral anticoagulants (DOACs) could partially overcome these issues, but until recently there were no large clinical trials assessing their efficacy and safety in cancer patients. This review summarizes clinical treatment guidelines, prior clinical and real-world evidence for anticoagulant choice, recent clinical trials assessing DOACs for cancer-associated VTE (i.e. Hokusai-VTE Cancer, SELECT-D, CARAVAGGIO, and ADAM VTE), and special considerations for DOAC use. Based on established data, clinical guidelines recommend patients with cancer-associated VTE receive LMWH treatment of at least 3-6 months. Nevertheless, LMWH is underused and associated with poor compliance and persistence in these patients relati